Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2005-12-28
2008-09-02
Mondesi, Robert B. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600
Reexamination Certificate
active
07420031
ABSTRACT:
An amino acid sequence Arg-Lys-Met-Leu-Lys-Ser-Thr-Arg-Arg-Gln-Arg-Arg (SEQ ID NO:1) functions as a protein transduction domain (PTD) and is capable of delivering small molecules, proteins, and nucleic acids to an intracellular compartment of a cell. An amino terminal lysine linker improves the efficiency of the PTD. A nuclear localization signal can be used to target the PTD to a cell's nucleus. The PTD can be used in PTD-cargo moiety complexes that can reversibly immortalize cells and increase cell viability in culture.
REFERENCES:
patent: 5652122 (1997-07-01), Frankel et al.
patent: 5670617 (1997-09-01), Frankel et al.
patent: 5674980 (1997-10-01), Frankel et al.
patent: 5747641 (1998-05-01), Frankel et al.
patent: 5804604 (1998-09-01), Frankel et al.
patent: 5807746 (1998-09-01), Lin et al.
patent: 6093809 (2000-07-01), Cech et al.
patent: 6166178 (2000-12-01), Cech et al.
patent: 6261836 (2001-07-01), Cech et al.
patent: 6306993 (2001-10-01), Rothbard et al.
patent: 6358739 (2002-03-01), Baetge et al.
patent: 2002/0009491 (2002-01-01), Rothbard et al.
patent: 2004/0209797 (2004-10-01), Karas
patent: 0 841 396 (1996-05-01), None
patent: WO-99/50386 (1999-10-01), None
patent: WO-00/34308 (2000-06-01), None
patent: WO-00/61617 (2000-10-01), None
patent: WO-00/62067 (2000-10-01), None
patent: WO 01/15511 (2001-03-01), None
Schwarze et al., “Protein transduction: unrestricted delivery into all cells?”, Trends in Cell Biology 10: 290-295 (2000).
Wender, et al., “The design, synthesis, and evaluation of melecules that enable or enhance cellular uptake: Peptoid molecular transmporters” PNAS, vol. 97, No. 24, Nov. 21, 2000, pp. 13003-13008.
Walther, et al., “Expression of Granulosa Cell-Specific Genes and Induction of Apoptosis in Conditionally Immortalized Granulosa Cell Lines Established from H-2Kb-tsA58 Transgenic Mice” Biology of Reproduction, vol. 60, 1999, pp. 1078-1086.
Ho, et al., “Synthetic Protein Transduction Domains: Enhanced Transduction Potential in Vitro and in Vivo1” Cancer Research, vol. 61, Jan. 15, 2001, pp. 474-477.
Asoh, et al., “Protection against ischemic brain injury by protein therapeutics” PNAS, vol. 99, No. 26, Dec. 24, 2002, pp. 17107-17112.
Cao, et al., “In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis” Jorunal of Neuroscience, vol. 22, No. 13, Jul. 1, 2002, pp. 5423-5431.
Pierce Chemical Technical Library, “Cross—Linking: Homobifunctional Cross-linkers” http://www.piercenet.com.
Pierce Chemical Technical Library, “Cross—Linking: Heterobifunctional Cross-linkers” http://www.piercenet.com.
Pierce Chemical Technical Library, “Cross—Linking: Applications for Use of Cross-linkers” http://www.piercenet.com.
Pierce Chemical Technical Library, “Cross—Linking: Glossary of Cross-linking Terms” http://www.piercenet.com.
Conejero et al., “Glutamate and Antimitotic Agents Induce Differentiation, p53 Activation, and Apoptosis in Rodent Neostriatal Cell Lines Immortalized with the tsA58 Allele of SV40 Large Antigen,” 1999,Experimental Neurology, vol. 158, pp. 109-120.
Derer et al., “Direct Protein Transfer to Terminally Differentiated Muscle Cells,” 1999,J. Mol. Med., vol. 77, pp. 609-613.
Guenal et al., “Bcl-2 and Hsp27 Act at Different Levels to Suppress Programmed Cell Death,” 1997,Oncogene, vol. 15, pp. 347-360.
Kim et al., “Survival of Conditionally Immortalized Hepatocytes in the Spleen of Syngeneic Rats,” 2001,Journal of Gastroenterology and Hepatology, vol. 16, pp. 52-60.
Mi et al., “Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction in Vitro and in Vivo,” Oct. 2000,Molecular Therapy, vol. 2, No. 4, pp. 339-347.
Morris et al., “A Peptide Carrier for the Delivery of Biologically Active Proteins into Mammalian Cells,” Dec. 2001,Nature Biotechnology, vol. 19, pp. 1173-1176.
Schwartz& Zhang, “Peptide-Mediated Cellular Delivery,” 2000,Current Opinion in Molecular Therapeutics, vol. 2(2) (5 pages).
Urquidi et al. “Role of Telomerase in Cell Senescence and Oncogenesis,” 2000,Ann. Rev. Med., vol. 51, pp. 65-79.
Vocero-Akbani et al., “Protein Transduction: Delivery of Tat-GTPase Fusion Proteins into Mammalian Cells,”Regulators and Effectors of Small GTPases, vol. 332, pp. 36-49, 2001.
Wadia & Dowdy, “Protein Transduction Technology,” 2002,Curr. Opin. Biotechnology, vol. 13, pp. 52-56.
Dietz et al., “Inhibition of Neuronal Apoptosis in Vitro and in Vivo Using TAT-Mediated Protein Transduction”,Molecular and Cellular Neuroscience, 2002, pp. 29-37, vol. 21.
Fawall et al., “Tat-mediated delivery of heterologous proteins into cells”, Biogen Inc., Oct. 7, 1993, pp. 664-668.
Banner & Witcoff , Ltd.
Desai Anand U
Lonza Walkersville, Inc.
Mondesi Robert B.
LandOfFree
Intracellular delivery of small molecules, proteins, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intracellular delivery of small molecules, proteins, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intracellular delivery of small molecules, proteins, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981078